Allan J Fox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Allan J Fox has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
A.J. Molyneux
Oxford Neurovascular and Neuroradiology Research Unit (ONNRU), University of Oxford, Oxford, UK
1 shared publication- Andrew J Molyneux
Oxford Neurovascular & Neuroradiology Research Unit, University of Oxford, Oxford, UK
1 shared publication D. Roy
Department of Neuroradiology, Hôpital Notre Dame, Université de Montréal, Montréal, Ontario, Canada
1 shared publication- George Tomlinson
Insitute of Heath Policy, Management and Evaluation, University of Toronto, Toronto General Hospital Research Institute, Toronto, ON, Canada
1 shared publication - Guylaine Gevry
Centre Hospitalier de l'Université de Montréal (CHUM), Research Centre, Interventional Neuroradiology Laboratory, Montreal, Quebec, CANADA
1 shared publication - Isabelle Rouleau
Département de Psychologie, Université du Québec à Montréal, Montréal, QC H2X 3P2, Canada
1 shared publication
Latest Publications
- Open Access
- 27 November 2008
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 30 (3) , 459-461
Dangerous Advances in Measurements from Digital Subtraction Angiography: When Is a Millimeter Not a Millimeter?: Fig 1.
SUMMARY: Aneurysms need accurate millimeters (mm). Direct millimeters were lost with digital subtraction angiography (DSA) years ago, with measurements in pixels. Advances in DSA can now give inherent millimeters. The Cerecyte aneurysm coiling trial's angiographic core lab assesses images from compact disc (CD). External fiducials for millimeter calibration are required. Of 25 cases with two 10 mm fiducials, near and far from the intensifier, the midline mean is between 9 “mm” to 15 “mm”. Yet 10 mm must be 10 mm. This variance is potentially dangerous. Proprietary software seems to prohibit calibration transfer via CD to another vendor's system.
- 27 November 2008
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 30 (3) , 459-461
Open AccessDangerous Advances in Measurements from Digital Subtraction Angiography: When Is a Millimeter Not a Millimeter?: Fig 1.
SUMMARY: Aneurysms need accurate millimeters (mm). Direct millimeters were lost with digital subtraction angiography (DSA) years ago, with measurements in pixels. Advances in DSA can now give inherent millimeters. The Cerecyte aneurysm coiling trial's angiographic core lab assesses images from compact disc (CD). External fiducials for millimeter calibration are required. Of 25 cases with two 10 mm fiducials, near and far from the intensifier, the midline mean is between 9 “mm” to 15 “mm”. Yet 10 mm must be 10 mm. This variance is potentially dangerous. Proprietary software seems to prohibit calibration transfer via CD to another vendor's system.
- Open Access
- 16 July 2008
- Published by Springer Nature in Trials
- Vol. 9 (1) , 43
The TEAM trial: Safety and efficacy of endovascular treatment of unruptured intracranial aneurysms in the prevention of aneurysmal hemorrhages: A randomized comparison with indefinite deferral of treatment in 2002 patients followed for 10 years
The management of patients with unruptured aneurysms remains controversial. Patients with unruptured aneurysms may suffer intracranial haemorrhage, but the incidence of this event is still debated; endovascular treatment may prevent rupture, but involves immediate risks. Hence, the balance of risks and benefits of endovascular treatment is uncertain. Here, we report the design of the TEAM trial, the first international, randomized, controlled trial comparing conservative management with endovascular treatment. Primary endpoint is mortality and morbidity (modified Rankin Score >/= 3) from intracranial haemorrhage or treatment. Secondary endpoints include incidence of hemorrhagic events, morbidity related to endovascular coiling, morphological results, overall clinical outcome and quality of life. Statistical tests compare between probabilities at 5- and 10-years of 1) mortality from haemorrhage related to the lesion, excluding per-operative complications; 2) mortality from haemorrhage or from complications of treatment; 3) combined disease or treatment related mortality and morbidity in the absence of other causes of death or disability. The study will be conducted in 60 international centres and will enroll 2,002 patients equally divided between the two groups, a size sufficient to achieve 80% power at a 0.0167 significance to detect differences in 1) disease or treatment-related poor outcomes from 7-9% to 3-5%; 2) overall mortality from 16 to 11%. Duration of the study is 14 years, the first three years being for patient recruitment plus a minimum of 10 years of follow-up. The TEAM trial thus offers a means to reconcile the introduction of a new approach with the necessity to acknowledge uncertainties. Current Controlled Trials ISRCTN62758344 http://www.controlled-trials.com.
- 16 July 2008
- Published by Springer Nature in Trials
- Vol. 9 (1) , 43
Open AccessThe TEAM trial: Safety and efficacy of endovascular treatment of unruptured intracranial aneurysms in the prevention of aneurysmal hemorrhages: A randomized comparison with indefinite deferral of treatment in 2002 patients followed for 10 years
The management of patients with unruptured aneurysms remains controversial. Patients with unruptured aneurysms may suffer intracranial haemorrhage, but the incidence of this event is still debated; endovascular treatment may prevent rupture, but involves immediate risks. Hence, the balance of risks and benefits of endovascular treatment is uncertain. Here, we report the design of the TEAM trial, the first international, randomized, controlled trial comparing conservative management with endovascular treatment. Primary endpoint is mortality and morbidity (modified Rankin Score >/= 3) from intracranial haemorrhage or treatment. Secondary endpoints include incidence of hemorrhagic events, morbidity related to endovascular coiling, morphological results, overall clinical outcome and quality of life. Statistical tests compare between probabilities at 5- and 10-years of 1) mortality from haemorrhage related to the lesion, excluding per-operative complications; 2) mortality from haemorrhage or from complications of treatment; 3) combined disease or treatment related mortality and morbidity in the absence of other causes of death or disability. The study will be conducted in 60 international centres and will enroll 2,002 patients equally divided between the two groups, a size sufficient to achieve 80% power at a 0.0167 significance to detect differences in 1) disease or treatment-related poor outcomes from 7-9% to 3-5%; 2) overall mortality from 16 to 11%. Duration of the study is 14 years, the first three years being for patient recruitment plus a minimum of 10 years of follow-up. The TEAM trial thus offers a means to reconcile the introduction of a new approach with the necessity to acknowledge uncertainties. Current Controlled Trials ISRCTN62758344 http://www.controlled-trials.com.